It is currently Sat Nov 22, 2014 7:48 am

News News of Copaxone

Site map of Copaxone » Forum : Copaxone

A board to discuss the Multiple Sclerosis modifying drug Copaxone

Lipoatrophy Survey

Of all of you who are on Copaxone and how old you are and if you're male or female. I've heard that males tend to get it less, or not at all, and I was just wondering.
Read more : Lipoatrophy Survey | Views : 5735 | Replies : 19


Copaxone cuts risk of developing MS-

-In 481 patients presenting with a first flare and confirming MRI, but no definitive diagnosis.

In the interim analysis, the proportion of patients developing clinically definite multiple sclerosis (re: a second flare) was 43 percent in the placebo group compared with 25 percent in the Copaxone group, Teva said.

For those that received a clinical diagnosis of MS- the second attack was delayed to 722 days, vs. the 2nd attack average of 366 days in ...
Read more : Copaxone cuts risk of developing MS- | Views : 2305 | Replies : 1


Ouch!

I have been doing Copaxone injections for almost 5 years. I have dealt with lipoatrophy (which I chalked it up to the price you have to pay with this drug) stinging injections, and some hives. None of this has caused me to want to stop because I have felt I have benefitted from this drug. But I nearly went through the roof with my injection last night! Injected into my thigh (as I have done ...
Read more : Ouch! | Views : 3439 | Replies : 12


United Arab Emirates, Abu Dhabi

Does anyone know if Copaxone is available in Abu Dhabi in the U.A. E.? I am hoping to relocate there, but only if I can continue treatment.
Read more : United Arab Emirates, Abu Dhabi | Views : 2091 | Replies : 1


Copaxone long-term study

Now that's some long-term follow up!



Long-term (up to 22 years), open-label,compassionate-use study of glatiramer acetatein relapsingremitting multiple sclerosis.

Mult Scler. 2008 Jan 21
Miller A, Spada V, Beerkircher D, Kreitman RR.
Mount Sinai School of Medicine, New York, NY, USA.

To evaluate the safety and efficacy of long-term glatiramer acetate (GA) therapy, 46 patients with relapsingremitting multiple sclerosis (RRMS) were treated for up to 22 years in an ongoing, open-label ...
Read more : Copaxone long-term study | Views : 3630 | Replies : 5


Hives, copaxone - need information

Hello, I searched and the topic hives was already discussed, but though I´m askink. Did anybody have hives? I have terrible hives for 14 days (now I ´m hospitalized on cortizone cure, which helps, but when it stops, it appears again). I use copaxone 1 year and had no problems so far, but my neuro said, she couldn´t separete out the copaxone like a reason of hives. That´s why I don´t continue with copaxone now ...
Read more : Hives, copaxone - need information | Views : 6404 | Replies : 9


Reimported Cop

Anyone else have a problem with reimported Cop?
The online chemist buys it where it's cheapest, good for him. At the moment it is cheaper if he buys reimports from France. Each syringe has a little sticker on it over the French text, saying the same stuff in German. The little stickers prevent the syringes from fitting properly in the autoinjector sometimes.
Anyway, the first one of these vials got stuck in the injector and ...
Read more : Reimported Cop | Views : 1969 | Replies : 1


Effects of Copaxone

"Neuroprotection… Neurogenesis… Newborn neurons migrating to the site of injury…" all these words get me really excited – do they do that to anyone else, or am I just pathetically easy to please?

Neurogenesis and neuroprotection in the CNS - fundamental elements in the effect of glatiramer acetate on treatment of autoimmune neurological disorders.
Mol Neurobiol. 2007 Dec;36(3):245-53
Authors: Arnon R, Aharoni R
Multiple sclerosis (MS) is no longer considered to be simply an autoimmune ...
Read more : Effects of Copaxone | Views : 2439 | Replies : 1




Study finds little difference in Copaxone v Rebif trial

Merck KGaA's Rebif multiple-sclerosis drug is not superior to rival Teva's Copaxone, a study obtained by Reuters on Wednesday showed.
"The number of events (relapses) was insufficient to establish a statistically significant difference between the two products, despite a trend advantage for Rebif," the report said.

The 96-week Phase IV study involving almost 800 patients will be presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague.

Merck inherited Rebif ...
Read more : Study finds little difference in Copaxone v Rebif trial | Views : 2216 | Replies : 3


 

Login  •  Register


Statistics

Total posts 221679 • Total topics 23015 • Total members 14539


Contact us | Terms of Service